CONGRESS PRESENTATIONS

CONGRESS PRESENTATIONS

CROI 2024

Denver, Colorado
March 3-6, 2024

  • Cabotegravir Prevention

    Liu A, et. al.

    Healthcare staff acceptability and feasibility of telehealth delivery of cabotegravir for PrEP

    View Poster

  • Cabotegravir Treatment

    Latham C, et. al.

    HIV-1 RNA Blips and Low-Level Viral Replication: SOLAR (CAB+RPV LA vs. BIC/FTC/TAF)

    View Poster

    Han K, et. al.

    Model Based Comparison of Cabotegravir Pharmacokinetics following Thigh and Gluteal Injections

    View Poster

  • Dolutegravir-based Regimens

    Sörstedt E, et al.

    Switching to DTG+3TC vs 3-drug regimens in routine clinical care: Long-term Swedish data

    View Poster

  • Pipeline

    Ferris R, et. al.

    Temsavir Treatment Enhances bnAb Recognition and Subsequent Clearance of HIV-1 Infected Cells

    View Poster

    Jeffrey J, et. al.

    Next-Generation Maturation Inhibitor GSK3640254 Showed Broad Spectrum Potency Without MI Resistance

    View Poster

    McAuliffe B, et. al.

    The preclinical profile of maturation inhibitor VH3739937

    View Poster

    Win B, et. al.

    High-Dose VH3810109 (N6LS) ± Recombinant Human Hyaluronidase PH20: Phase I SPAN Study Safety Results

    View Poster

    Han K, et. al.

    Phase I Study of Cabotegravir Long-Acting Injectable Formulations Supports ≥4-Monthly Dose Interval

    View Poster

    Leone P, et. al.

    VH3810109 (N6LS) in Antiretroviral Therapy–Naive Adults With HIV-1: Phase IIa BANNER Efficacy Data

    View Poster
ViiV Medical Webinar asset

2024 Post CROI Conference

Scientific Engagement Webinar - with panel discussion and audience Q&A

On Demand